Accentia Biopharmaceuticals to Present at BioCentury “Future Leaders in Biotech” Conference in New York

TAMPA, Fla.--(BUSINESS WIRE)--Accentia Biopharmaceuticals, Inc. (NASDAQ:ABPI) today announced that the Company is scheduled to present at the BioCentury / Thomson Financial “Future Leaders in the Biotech Industry” Conference on Thursday, March 27^th. The presentation will be available on a live and archived basis, accessible at the Company’s website.

Accentia’s BioCentury Presentation details are as follows:

--		Event: BioCentury / Thomson Financial "Future Leaders in the
		Biotech Industry"
		Presenter: Dr. Frank E. O'Donnell, Jr., Chairman, CEO and Founder
		When: Thursday, March 27, 2008 at 2:30 - 2:55 p.m.
		Where: Millennium Broadway Hotel, New York City, Room 302/303
		Address: 145 West 44th Street, New York, NY, 10036
		Breakout Session: 3:00 - 4:00 p.m., Room 301
		Webcast Link Available at: http://www.accentia.net

Accentia anticipates reporting a significant milestone in April, as the Company’s majority-owned subsidiary, Biovest International, Inc. (OTCBB:BVTI), is preparing to report the interim unblinded results of its pivotal Phase 3 study for the anti-cancer vaccine, BiovaxID™. These results, if positive, are expected to poise BiovaxID to become the first personalized anti-cancer vaccine to ever be granted approval for the treatment of non-Hodgkin’s lymphoma.

As recently reported, Accentia is also awaiting a full data analysis for its Phase 3 clinical trial evaluating SinuNase™ for the treatment of chronic sinusitis (CS). SinuNase lavage demonstrated superiority to placebo control lavage in resolving two cardinal symptoms of CS (nasal congestion and sinus headache), and while the primary endpoint did not reach the 95% confidence level of statistical significance, the Company continues to believe that the additional data that is pending, including composite symptom scores, and objective measurements of fungal-induced inflammation such as CT scans, endoscopy, and biomarkers in nasal mucus will provide evidence of additional superior clinical benefit.

About Accentia Biopharmaceuticals, Inc.

Accentia Biopharmaceuticals, Inc. is a portfolio company of the Hopkins Capital Group, LLC. It is organized as a vertically integrated biopharmaceutical company focused on the development and commercialization of drug candidates that are in late-stage clinical development and typically are based on active pharmaceutical ingredients that have been previously approved by the FDA for other indications. Usually these drug candidates can access the accelerated 505(b)(2) regulatory approval pathway, which is generally less time-consuming, and less expensive than the typical 505(b)(1) pathway that must be used for new chemical entities, which typically have a higher risk profile. The Company’s lead product candidate is SinuNase™, a novel application and formulation of a known therapeutic to treat chronic rhinosinusitis. SinuNase has been granted Fast Track status by the FDA and it is currently in a pivotal Phase 3 clinical trial. During this fiscal year, the Company also plans to file an Investigative New Drug (IND) for a pivotal Phase 3 clinical trial of Revimmune™, to treat numerous autoimmune diseases with an initial indication targeting refractory relapsing-remitting Multiple Sclerosis. Revimmune is based on pulsed, ultra-high dosing of a well-known chemotherapeutic agent under a risk management program. Additionally, through an investment strategy, the Company has acquired the majority ownership interest in Biovest International, Inc. (OTCBB:BVTI) and a royalty interest in Biovest’s lead drug candidate, BiovaxID® and any other biologic products developed by Biovest. Biovest is currently conducting a pivotal Phase 3 clinical trial for BiovaxID which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin’s lymphoma. BiovaxID has been granted Fast Track status by the FDA. In addition to these product candidates, the Company has a specialty pharmaceutical business, which markets products focused on respiratory disease and an analytical consulting business that serves customers in the biopharmaceutical industry.

For further information, please visit: http://www.Accentia.net.

Forward-Looking Statements:

Statements in this release that are not strictly historical in nature constitute "forward-looking statements." Such statements include, but are not limited to, statements about Revimmune™, SinuNase™, BiovaxID®, AutovaxID™, SinuTest™, AllerNase™ and any other statements relating to products, product candidates, product development programs, the FDA or clinical study process including the commencement, process, or completion of clinical trials or the regulatory process. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, expectations and intentions, and other statements identified by words such as "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results of Accentia to be materially different from historical results or from any results expressed or implied by such forward-looking statements. These factors include, but are not limited to, risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval for product candidates; competition from other pharmaceutical or biotechnology companies; and the additional risks discussed in filings with the Securities and Exchange Commission. All forward-looking statements are qualified in their entirety by this cautionary statement, and Accentia undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. The product names used in this statement are for identification purposes only. All trademarks and registered trademarks are the property of their respective owners.